Hypertension, Pulmonary Clinical Trial
— VOLTOfficial title:
A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)
| Verified date | March 2017 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
| Status | Completed |
| Enrollment | 800 |
| Est. completion date | July 2013 |
| Est. primary completion date | July 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label) |
| Country | Name | City | State |
|---|---|---|---|
| Australia | GSK Investigational Site | Chermside | Queensland |
| Australia | GSK Investigational Site | Darlinghurst | New South Wales |
| Australia | GSK Investigational Site | Melbourne | Victoria |
| Belgium | GSK Investigational Site | Brussels | |
| Belgium | GSK Investigational Site | Leuven | |
| Canada | GSK Investigational Site | Edmonton | Alberta |
| Canada | GSK Investigational Site | Halifax | Nova Scotia |
| Canada | GSK Investigational Site | London | Ontario |
| Canada | GSK Investigational Site | Montreal | Quebec |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Vancouver | British Columbia |
| Canada | GSK Investigational Site | Winnipeg | Manitoba |
| Czech Republic | GSK Investigational Site | Praha 2 | |
| Czech Republic | GSK Investigational Site | Praha 4 | |
| Denmark | GSK Investigational Site | Aarhus N | |
| France | GSK Investigational Site | Besançon | |
| France | GSK Investigational Site | Bordeaux | |
| France | GSK Investigational Site | Brest | |
| France | GSK Investigational Site | Bron | |
| France | GSK Investigational Site | Caen Cedex 5 | |
| France | GSK Investigational Site | Clamart | |
| France | GSK Investigational Site | Grenoble | |
| France | GSK Investigational Site | Lille | |
| France | GSK Investigational Site | Lille cedex | |
| France | GSK Investigational Site | Marseille cedex 20 | |
| France | GSK Investigational Site | Marseille cedex 5 | |
| France | GSK Investigational Site | Montpellier | |
| France | GSK Investigational Site | Nantes cedex 1 | |
| France | GSK Investigational Site | Pessac cedex | |
| France | GSK Investigational Site | Poitiers cedex | |
| France | GSK Investigational Site | Reims | |
| France | GSK Investigational Site | Rennes cedex 9 | |
| France | GSK Investigational Site | Rouen Cedex | |
| France | GSK Investigational Site | Strasbourg | |
| France | GSK Investigational Site | Toulouse | |
| France | GSK Investigational Site | Tours cedex 9 | |
| France | GSK Investigational Site | Vandoeuvre-Les-Nancy | |
| Germany | GSK Investigational Site | Aachen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Cottbus | Brandenburg |
| Germany | GSK Investigational Site | Donaueschingen | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Dresden | Sachsen |
| Germany | GSK Investigational Site | Essen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Freiburg | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Gerlingen | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Giessen | Hessen |
| Germany | GSK Investigational Site | Greifswald | Mecklenburg-Vorpommern |
| Germany | GSK Investigational Site | Grosshansdorf | Schleswig-Holstein |
| Germany | GSK Investigational Site | Hamburg | |
| Germany | GSK Investigational Site | Hannover | Niedersachsen |
| Germany | GSK Investigational Site | Heidelberg | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Heidelberg | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Koeln | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Leipzig | Sachsen |
| Germany | GSK Investigational Site | Loewenstein | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Luebeck | Schleswig-Holstein |
| Germany | GSK Investigational Site | Mainz | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Moers | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Muenchen | Bayern |
| Germany | GSK Investigational Site | Regensburg | Bayern |
| Germany | GSK Investigational Site | Solingen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Treuenbrietzen | Brandenburg |
| Germany | GSK Investigational Site | Ulm | Baden-Wuerttemberg |
| Greece | GSK Investigational Site | Alexandroupolis | |
| Greece | GSK Investigational Site | Athens | |
| Greece | GSK Investigational Site | Thessaloniki | |
| Greece | GSK Investigational Site | Thessaloniki | |
| Greece | GSK Investigational Site | Voula / Athens | |
| Italy | GSK Investigational Site | Bologna | Emilia-Romagna |
| Italy | GSK Investigational Site | Catania | Sicilia |
| Italy | GSK Investigational Site | Firenze | Toscana |
| Italy | GSK Investigational Site | Napoli | Campania |
| Italy | GSK Investigational Site | Orbassano (TO) | Piemonte |
| Italy | GSK Investigational Site | Palermo | Sicilia |
| Italy | GSK Investigational Site | Pavia | Lombardia |
| Italy | GSK Investigational Site | Pisa | Toscana |
| Italy | GSK Investigational Site | Roma | Lazio |
| Netherlands | GSK Investigational Site | Amsterdam | |
| Netherlands | GSK Investigational Site | Amsterdam | |
| Netherlands | GSK Investigational Site | Groningen | |
| Netherlands | GSK Investigational Site | Maastricht | |
| Netherlands | GSK Investigational Site | Nieuwegein | |
| Netherlands | GSK Investigational Site | Nijmegen | |
| Netherlands | GSK Investigational Site | Rotterdam | |
| Norway | GSK Investigational Site | Bergen | |
| Norway | GSK Investigational Site | Oslo | |
| Slovakia | GSK Investigational Site | Bratislava | |
| Slovakia | GSK Investigational Site | Kosice | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Córdoba | |
| Spain | GSK Investigational Site | Madrid | |
| Spain | GSK Investigational Site | Madrid | |
| Spain | GSK Investigational Site | Malaga | |
| Spain | GSK Investigational Site | Ourense | |
| Spain | GSK Investigational Site | Pontevedra | |
| Spain | GSK Investigational Site | Sevilla | |
| Spain | GSK Investigational Site | Toledo | |
| Spain | GSK Investigational Site | Valencia | |
| Sweden | GSK Investigational Site | Göteborg | |
| Sweden | GSK Investigational Site | Linköping | |
| Sweden | GSK Investigational Site | Lund | |
| Sweden | GSK Investigational Site | Umeå | |
| Sweden | GSK Investigational Site | Uppsala | |
| United Kingdom | GSK Investigational Site | Cambridge | |
| United Kingdom | GSK Investigational Site | Clydebank | |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | Newcastle upon Tyne | |
| United Kingdom | GSK Investigational Site | Sheffield |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
Australia, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | safety monitoring | |||
| Secondary | safety monitoring |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
| Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
| Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
| Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
| Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
| Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
| Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
| Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
| Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
| Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
| Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
| Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
| Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
| Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
| Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
| Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
| Completed |
NCT01178073 -
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 |